中國生物製藥(01177.HK)抗炎鎮痛藥"注射用帕瑞昔布鈉"獲通過一致性評價
格隆匯 2 月 9日丨中國生物製藥(01177.HK)宣佈,集團的抗炎鎮痛產品"注射用帕瑞昔布鈉"(商品名:芬可欣)(規格:40mg)已獲中華人民共和國國家藥品監督管理局頒發藥品補充申請批准通知書,獲通過仿製藥質量和療效一致性評價。
帕瑞昔布作為全球第一個可供靜脈注射或肌內注射用的選擇性氧化酶-2(COX-2)抑制劑,在臨牀上適用於術後疼痛的短期治療,其臨牀療效已經在口腔科、婦科、骨科等多種手術術後的止痛治療中得到證實,並且術後靜脈給予該藥品可減少嗎啡用量,提高術後鎮痛質量。臨牀研究證實其安全有效,且患者耐受性好,胃腸道不良反應發生率低,不會出現胃腸道黏膜潰瘍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.